The Simplified Test Protocol, developed in our earlier studies for testing personal inhalable aerosol samplers, was evaluated in a specially designed small open-section, close-loop wind tunnel. The sampling efficiencies of three personal inhalable aerosol samplers (IOM, GSP, and Button Aerosol Sampler) were measured with 65 mum particles, using the Simplified Test Protocol at four inlet orientations to the wind (0, 90, 180? and 270 degrees). The results were compared with the data collected from other evaluation approaches. Analysis of variance (ANOVA) has shown that there is no statistically significant difference in the samplers performance when they are tested in the small and large wind tunnels following the Simplified Test Protocol and in the large wind tunnel following the conventional approach (samplers on a full-size human manikin). Thus, the Simplified Test Protocol has been shown to be suitable for the performance evaluation of personal inhalable aerosol samplers. The new wind tunnel facility was also found useful for handling very large particles, which is a considerable advantage over traditional wind tunnels. Our new wind tunnel was successfully used to measure the sampling efficiencies of the IOM, GSP, and Button Aerosol Sampler when challenged with particles of up to approximately 250 mum aerodynamic diameter at wind velocities of 50 and 100 cm s(-1). The data show that the sampling efficiency of the IOM sampler depends significantly on the wind velocity and is above 100% for particles of 165 and 241 mum mass median aerodynamic diameter. This dependence is not statistically significant for the GSP and Button Aerosol Sampler, whose sampling efficiencies are similar to each other and do not change with increasing test particle size at the indicated wind velocities. Also, the sampling efficiencies of the GSP and Button Aerosol Sampler closely follow the independent data obtained by using a breathing and rotating manikin at a wind velocity of 100 cm s(-1). The new wind tunnel design is expected to enhance the ability to extend the inhalable convention beyond 100 mum.